These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38916781)

  • 1. Recurrent symptomatic urolithiasis in a patient with cystic fibrosis.
    Yel S; Dursun I; Köse M; Kiraz A; Poyrazoglu MH; Dündar M
    Pediatr Nephrol; 2024 Jun; ():. PubMed ID: 38916781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic characterization of Chinese pediatric cystine stone patients.
    Shen L; Cong X; Zhang X; Wang N; Zhou P; Xu Y; Zhu Q; Gu X
    J Pediatr Urol; 2017 Dec; 13(6):629.e1-629.e5. PubMed ID: 28689648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic risk factors for stone formation in patients with cystic fibrosis.
    Perez-Brayfield MR; Caplan D; Gatti JM; Smith EA; Kirsch AJ
    J Urol; 2002 Feb; 167(2 Pt 1):480-4. PubMed ID: 11792901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic disturbances in Chinese children with urolithiasis: a single center report.
    Yang D; Tiselius HG; Lan C; Chen D; Chen K; Ou L; Liu Y; Xu S; Zeng G; Lei M; Wu W
    Urolithiasis; 2017 Jun; 45(3):285-290. PubMed ID: 27510800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome.
    Wannous H
    Pediatr Nephrol; 2023 Aug; 38(8):2643-2648. PubMed ID: 36917293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and Clinical Characteristics of Children with Urolithiasis from Southern India.
    Ramya K; Krishnamurthy S; Manikandan R; Sivamurukan P; Naredi BK; Karunakar P
    Indian J Pediatr; 2021 Apr; 88(4):345-350. PubMed ID: 32737767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric urolithiasis--evaluation of risk factors in 95 children.
    Erbagci A; Erbagci AB; Yilmaz M; Yagci F; Tarakcioglu M; Yurtseven C; Koyluoglu O; Sarica K
    Scand J Urol Nephrol; 2003; 37(2):129-33. PubMed ID: 12745721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene.
    Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Hyperoxaluria Type 1: A Cause for Infantile Renal Failure and Massive Nephrocalcinosis.
    Kurt-Sukur ED; Özçakar ZB; Fitöz S; Yilmaz S; Hoppe B; Yalçinkaya F
    Klin Padiatr; 2015 Sep; 227(5):293-5. PubMed ID: 26090995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis.
    Böhles H; Gebhardt B; Beeg T; Sewell AC; Solem E; Posselt G
    J Pediatr; 2002 Jan; 140(1):103-9. PubMed ID: 11815772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperoxaluria and urolithiasis in young children: an atypical presentation.
    Monico CG; Milliner DS
    J Endourol; 1999 Nov; 13(9):633-6. PubMed ID: 10608514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal Oxalate Absorption, Enteric Hyperoxaluria, and Risk of Urinary Stone Formation in Patients with Crohn's Disease.
    Siener R; Ernsten C; Speller J; Scheurlen C; Sauerbruch T; Hesse A
    Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria.
    Sidhu H; Hoppe B; Hesse A; Tenbrock K; Brömme S; Rietschel E; Peck AB
    Lancet; 1998 Sep; 352(9133):1026-9. PubMed ID: 9759746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stone growth patterns and risk for surgery among children presenting with hypercalciuria, hypocitraturia and cystinuria as underlying metabolic causes of urolithiasis.
    Zu'bi F; Sidler M; Harvey E; Lopes RI; Hojjat A; Naoum N; Pokarowski M; Lorenzo AJ; Farhat WA; Papanikolaou F; Dos Santos J
    J Pediatr Urol; 2017 Aug; 13(4):357.e1-357.e7. PubMed ID: 28865885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis.
    Vaidyanathan S; von Unruh GE; Watson ID; Laube N; Willets S; Soni BL
    ScientificWorldJournal; 2006 Apr; 6():2403-10. PubMed ID: 17619709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric urolithiasis: metabolic risk factors and follow-up results in a Turkish region with endemic stone disease.
    Elmacı AM; Ece A; Akın F
    Urolithiasis; 2014 Oct; 42(5):421-6. PubMed ID: 25022263
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.